Cannabidiolic acid

DB19261InvestigationalSmall molecule

Cannabidiolic acid is under investigation in clinical trial NCT04103814 (Effect of Topical CBD Cream for Degenerative Hallux Disorders).

Mechanism: Pharmacologically active on Prostaglandin G/H synthase 2
Curator reviewed
Formula / weight: C₂₂H₃₀O₄ · 358.478 g/mol (avg)
Also known as: 3-p-mentha-1,8-dien-3-yl-6-pentyl-beta-resorcylic acid · Benzoic acid, 2,4-dihydroxy-3-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-6-pentyl- · Cannabidiolcarboxylic acid
Code names: CBDA

Resolves to

Compound

Structure

InChIKeyWVOLTBSCXRRQFR-DLBZAZTESA-NSMILESCCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1C(O)=O

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cannabidiolic acid, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.